Pliant Therapeutics, Inc. (PLRX)

Name: Pliant Therapeutics, Inc. (PLRX) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

SEC name PLIANT THERAPEUTICS, INC. · CIK 0001746473 · Nasdaq · Pharmaceutical Preparations

Sector Manufacturing
Incorporated DE
Fiscal year ends Dec 31

For the year ended 2025-12-31, Pliant Therapeutics, Inc. reported revenue of $0.

Key ratios (year ended 2025-12-31)

-82.4%

Return on year-end equity

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-02

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Revenue	n/a	$0	$0	$1.58M	$9.69M	$7.57M	$41.82M	$57.05M
R&D Expense	$63.83M	$109.16M	$169.31M	$127.80M	$96.94M	$77.55M	$66.19M	$47.35M
Operating Income	-$97.48M	-$156.37M	-$228.37M	-$184.15M	-$127.20M	-$97.53M	-$41.65M	-$1.23M
Net Income	-$92.29M	-$149.34M	-$210.30M	-$161.34M	-$123.32M	-$97.26M	-$41.53M	-$631.0K
EPS (Diluted)	n/a	-$2.43	-$3.47	-$2.75	-$2.94	-$2.71	-$1.95	-$4.22
Total Assets	$189.88M	$225.23M	$396.95M	$512.15M	$350.61M	$221.22M	$295.53M	$119.06M
Total Liabilities	$42.95M	$44.02M	$92.87M	$38.58M	$37.27M	$22.16M	$12.46M	$9.08M
Long-Term Debt	$0	$0	$30.21M	$10.05M	$9.93M	$0	n/a	n/a
Shareholders' Equity	$146.93M	$181.21M	$304.08M	$473.58M	$313.34M	$199.06M	$283.06M	-$76.30M
Cash & Equivalents	$24.88M	$45.45M	$71.19M	$63.23M	$33.69M	$51.66M	$50.88M	$85.81M
Operating Cash Flow	-$70.89M	-$128.34M	-$155.50M	-$116.36M	-$94.63M	-$75.44M	-$37.27M	-$2.75M
Capital Expenditures	$0	$374.0K	$3.85M	$921.0K	$1.76M	$1.95M	$1.53M	$964.0K
Free Cash Flow	-$70.89M	-$128.71M	-$159.35M	-$117.28M	-$96.39M	-$77.40M	-$38.80M	-$3.71M
Shares Outstanding	61.92M	61.45M	60.86M	59.92M	48.94M	36.08M	35.55M	1.85M
Dividends Per Share	n/a	$0.00	$0.00	$0.00	$0.00	$0.00	n/a	n/a
Weighted Average Diluted Shares	n/a	61.37M	60.54M	58.72M	42.02M	35.85M	21.34M	1.62M
EPS (Basic)	n/a	-$2.43	-$3.47	-$2.75	-$2.94	-$2.71	-$1.95	-$4.22

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView